Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 51Lymphoma, Mantle-Cell 48Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Lymphoma, Large-Cell, Immunoblastic 23Recurrence 20Lymphoma, B-Cell, Marginal Zone 17Leukemia, Lymphocytic, Chronic, B-Cell 17Immunoblastic Lymphadenopathy 17Lymphoma, T-Cell 16Neoplasms 14Dendritic Cell Sarcoma, Interdigitating 14Leukemia, Biphenotypic, Acute 10HIV Infections 10Enteropathy-Associated T-Cell Lymphoma 9Waldenstrom Macroglobulinemia 8Lymphoma, T-Cell, Cutaneous 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, Extranodal NK-T-Cell 7Cardiotoxicity 6

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Doxorubicin × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡